Biosplice Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies based on alternative pre-mRNA splicing to address unmet needs in osteoarthritis, oncology, and neurology. With significant backing from investors including aMoon Fund and Eventide, the company has raised substantial capital to advance its pipeline and expand research efforts.
Keep reading to learn how Biosplice built funding support and advanced its scientific platform.
What Is Biosplice Therapeutics and What Does It Do?
Founded in 2008, Biosplice Therapeutics is a United States based biotechnology company headquartered in San Diego, California, that pioneers first-in-class small-molecule therapeutics by harnessing the science of alternative pre-mRNA splicing. The company’s approach targets regulatory kinases to modulate tissue-specific splicing events, enabling potential treatments for degenerative conditions like osteoarthritis and expanding into oncology and neurological disease areas.
How Much Funding Has Biosplice Therapeutics Raised?
1. Venture Funding Round (Series D/Latest)
- Amount Raised: $120 million
- Date: April 2021
- Valuation: Approximately $12 billion (post-funding)
- Lead Investors: aMoon Fund, Eventide
- Other Investors: SymBiosis II, Sands Capital, Verition Fund Management, and others
- Purpose: Advance clinical development of lead programs and expand the therapeutic pipeline
2. Series C Round
- Amount Raised: Significant portion of cumulative funding
- Date: 2018–2019
- Lead Investors: aMoon Fund and strategic biotech investors
- Purpose: Expand biological platform research and build early clinical programs
3. Earlier Funding Activity (Seed to Series B)
- Seed & Series A: Initial capital to establish splicing modulation platform
- Series B: Expanded funding including participation from strategic biotech investors
- Purpose: Build scientific infrastructure, grow research teams, and progress early clinical candidates
Total Funding Raised: ~$778 million
Latest Funding Date: 2021
Latest Known Valuation: Approximately $12 billion
Key Investors
- aMoon Fund
- Details: Growth-oriented health care and life sciences investor
- Focus Areas: Biotech innovation, therapeutic platform technologies, and early clinical advancement
- Eventide
- Details: Investment firm focused on life sciences and biotechnology opportunities
- Focus Areas: Therapeutics development, scientific leadership, and strategic growth
- SymBiosis II
- Details: Biotech investor participating in major funding rounds
- Focus Areas: Precision medicine and novel therapy platforms
- Sands Capital
- Details: Growth-stage investor supporting technology and life science companies
- Focus Areas: Scientific innovation and therapeutic expansion
- Verition Fund Management
- Details: Institutional investment group participating alongside other strategic backers
- Focus Areas: Healthcare opportunities and biotech ventures
Where Is Biosplice Therapeutics’ Headquarters?
Biosplice Therapeutics is headquartered in San Diego, California, United States, serving as the central hub for its research, clinical operations, and strategic leadership in developing alternative splicing-based therapeutics.
What’s Next for Biosplice Therapeutics?
Biosplice continues progressing its clinical pipeline, including late-stage programs targeting osteoarthritis and expansion into oncology and neurological disease areas. The company is advancing its small-molecule splicing modulation technologies while expanding partnerships and exploring opportunities to bring transformative therapies to patients with high unmet medical needs.
Get Investor and Funding Insights with TexAu
TexAu provides verified investor and funding data for companies like Biosplice Therapeutics. Explore insights on biotechnology funding, therapeutic platform growth, and life science investments shaping the future of medicine.
Sign up for Free to access real time investor and funding intelligence.
